Gastrointestinal stromal tumors treated with imatinib mesylate: Apparent diffusion coefficient in the evaluation of therapy response in patients

Radiology

Volumn 258, Issue 3, 2011, Pages 729-738

  Tang, Lei ^a   Zhang, Xiao Peng ^a   Sun, Ying Shi ^a   Shen, Lin ^a   Li, Jian ^a   Qi, Li Ping ^a   Cui, Yong ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 79952287573     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10100402     Document Type: Article

References (40)

1. Rubin BP. Heinrich MC. Corless CL. Gastrointestinal stromal tumour. Lancet 2007;369(9574):1731-1741. (Pubitemid 46778870)
2. Graadt van Roggen JF. van Velthuysen ML. Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001;54(2):96-102.
3. Demetri GD. von Mehren M. Blanke CD. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-480.
4. Chow LQ. Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-896. (Pubitemid 350002890)
5. Sleijfer S. Wiemer E. Verweij J. Drug Insight: gastrointestinal stromal tumors (GIST) - the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol 2008;5(2):102-111. (Pubitemid 351188931)
6. Oldenhuis CN. Oosting SF. Gietema JA. de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008;44(7):946-953.
7. Gatenby RA. Silva AS. Gillies RJ. Frieden BR. Adaptive therapy. Cancer Res 2009;69(11):4894-4903.
8. Menu Y. Evaluation of tumour response to treatment with targeted therapies: standard or targeted criteria? [in French]. Bull Cancer 2007;94(7 suppl):F231-F239.
9. García-González J. Sánchez Salmón A. Areses Manrique C. León Mateos L. Barandela Salgado J. López López R. Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors [in Spanish]. Rev Esp Med Nucl 2007;26(2):100-102. (Pubitemid 46649393)
10. Stroszczynski C. Jost D. Reichardt P. et al. Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI. Eur Radiol 2005;15(12):2448-2456. (Pubitemid 43153845)
11. Hong X. Choi H. Loyer EM. Benjamin RS. Trent JC. Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. RadioGraphics 2006;26(2):481-495. (Pubitemid 43515319)
12. Choi H. Charnsangavej C. Faria SC. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13):1753-1759. (Pubitemid 46797957)
13. Tuma RS. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 2006;98(18):1272-1274.
14. Benjamin RS. Choi H. Macapinlac HA. et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25(13):1760-1764. (Pubitemid 46797958)
15. Suzuki C. Jacobsson H. Hatschek T. et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. RadioGraphics 2008;28(2):329-344.
16. Heinicke T. Wardelmann E. Sauerbruch T. Tschampa HJ. Glasmacher A. Palmedo H. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res 2005;25(6C):4591-4594. (Pubitemid 41729517)
17. Choi H. Charnsangavej C. de Castro Faria S. et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004;183(6):1619-1628.
18. Lassau N. Lamuraglia M. Chami L. et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 2006;187(5):1267-1273. (Pubitemid 44630831)
19. Bammer R. Basic principles of diffusionweighted imaging. Eur J Radiol 2003;45(3):169-184.
20. Patterson DM. Padhani AR. Collins DJ. Technology insight: water diffusion MRI - a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 2008;5(4):220-233. (Pubitemid 351493681)
21. Padhani AR. Liu G. Koh DM. et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11(2):102-125.
22. Kamel IR. Reyes DK. Liapi E. Bluemke DA. Geschwind JF. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007;18(1 pt 1):49-56. (Pubitemid 46616678)
23. Cui Y. Zhang XP. Sun YS. Tang L. Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008;248(3):894-900.
24. Pickles MD. Gibbs P. Lowry M. Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006;24(7):843-847. (Pubitemid 44205378)
25. Yankeelov TE. Lepage M. Chakravarthy A. et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 2007;25(1):1-13. (Pubitemid 46048940)
26. Sun YS. Zhang XP. Tang L. et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology 2010;254(1):170-178.
27. Kim SH. Lee JM. Hong SH. et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 2009;253(1):116-125.
28. Harry VN. Semple SI. Gilbert FJ. Parkin DE. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008;111(2):213-220.
29. Qi LP. Zhang XP. Tang L. Li J. Sun YS. Zhu GY. Using diffusion-weighted MR imaging for tumor detection in the collapsed lung: a preliminary study. Eur Radiol 2009;19(2):333-341.
30. Le Cesne A. Van Glabbeke M. Verweij J. et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 2009;27(24):3969-3974.
31. Belev B. Vrbanec D. Kralik M. Plestina S. Petricević B. Sirotković-Skerlev M. Gastrointestinal stromal tumors (GIST) - a paradigm of successful targeted therapy of solid tumors [in Croatian]. Acta Med Croatica 2006;60(5):471-475.
32. Tanaka S. Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 2009;100(1):1-8.
33. Keun Park C. Lee EJ. Kim M. et al. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg 2008;247(6):1011-1018. (Pubitemid 351770422)
34. Roth Y. Tichler T. Kostenich G. et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology 2004;232(3):685-692. (Pubitemid 39100249)
35. Thoeny HC. De Keyzer F. Chen F. et al. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 2005;234(3):756-764. (Pubitemid 40250819)
36. Hall DE. Moffat BA. Stojanovska J. et al. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res 2004;10(23):7852-7859. (Pubitemid 39587523)
37. Jennings D. Hatton BN. Guo J. et al. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 2002;4(3):255-262. (Pubitemid 34525257)
38. Roth Y. Tichler T. Kostenich G. et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology 2004;232(3):685-692. (Pubitemid 39100249)
39. Dzik-Jurasz A. Domenig C. George M. et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002;360(9329):307-308. (Pubitemid 34874724)
40. Deng J. Rhee TK. Sato KT. et al. In vivo diffusion-weighted imaging of liver tumor necrosis in the VX2 rabbit model at 1.5 Tesla. Invest Radiol 2006;41(4):410-414.